Clinical Trials Corner: September 2017

Journal of Huntington's Disease

Volumn 6, Issue 3, 2017, Pages 255-263

  Rodrigues, Filipe B ^a,b,c   Wild, Edward J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Clinical trials; Huntington's disease

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; CYTOPROTECTIVE AGENT; DEUTETRABENAZINE; IONIS HTTRX; LAQUINIMOD; MARDEPODECT; MEMANTINE; OLANZAPINE; PRIDOPIDINE; RESVERATROL; SBT 020; SRX 246; TETRABENAZINE; TRIHEPTANOIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VARENICLINE; VASOPRESSIN ANTAGONIST;

ALTERNATIVE MEDICINE; ARTICLE; BRAIN DEPTH STIMULATION; CELL TRANSPLANTATION; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDURANCE TRAINING; EXERCISE; HUMAN; HUNTINGTON CHOREA; MR-GUIDED FOCUSED ULTRASOUND; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; PROCEDURES;

CLINICAL TRIALS AS TOPIC; HUMANS; HUNTINGTON DISEASE;

EID: 85030309463     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-170262     Document Type: Article

References (24)

1. Ogino D, Takahashi K, Sato H. Characteristics of clinical trial websites: Information distribution between Clinical-Trials.gov and 13 primary registries in the WHO registry network. Trials. 2014;15:428.
2. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database-update and key issues. N Engl J Med. 2011;364(9):852-60.
3. Harriman SL, Patel J. When are clinical trials registered? An analysis of prospective versus retrospective registration. Trials. 2016;17:187.
4. Rodrigues FB, Mestre T, Duarte SD, Barra M, Costa J, Sampaio C, et al., editors.
5. Therapeutic interventions for symptomatic treatment in Huntington's disease-a Cochrane review. CHDI 12th Annual HD Therapeutics Conference; 2017; St Julien, Malta.
6. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology. 2006;66(3):366-72.
7. Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: A randomized clinical trial. JAMA. 2016;316(1):40-50.
8. Rodrigues FB, Mestre T, Duarte SD, Barra M, Costa J, Sampaio C, et al., editors. Therapeutic interventions for disease progression in Huntington's disease-a Cochrane review. CHDI 12th Annual HD Therapeutics Conference; 2017; St Julien, Malta.
9. Travessa AM, Rodrigues FB, Mestre TA, Ferreira JJ. Fifteen years of clinical trials in Huntington's disease: A very low clinical drug development success rate. J Huntingtons Dis. 2017;6(2):157-63.
10. Teva Branded Pharmaceutical Products R, Inc. D, Industries TP. A clinical study in subjects with Huntington's disease to assess the efficacy and safety of three oral doses of laquinimod. https://ClinicalTrials.gov/show/NCT02215616; 2014.
11. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol. 2004;156(1-2):3-9.
12. Huntington Study Group. Legato-HD Trial 2017 [Available from: Http://huntingtonstudygroup.org/current-clinical-trials/legato-hd-trial/
13. Ionis Pharmaceuticals I. Safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-HTTRx in patients with early manifest Huntington's disease. https://ClinicalTrials.gov/show/NCT02519036; 2015.
14. Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron. 2012;74(6):1031-44.
15. Carroll J, Maiuri T. Update confirms Huntington's disease 'gene silencing' trial on track 2017 [Available from: Https://en.hdbuzz.net/243.
16. Pfizer. Randomized, placebo controlled study of the efficacy and safety of PF-02545920 in subjects with Huntington's disease. https://ClinicalTrials.gov/show/NCT0219 7130; 2014.
17. Beaumont V, Zhong S, Lin H, Xu W, Bradaia A, Steidl E, et al. Phosphodiesterase 10A inhibition improves corticobasal ganglia function in Huntington's disease models. Neuron. 2016;92(6):1220-37.
18. Wild EJ, Carroll J. Pfizer Amaryllis trial ends in disappointment: No improvement in Huntington's disease symptoms 2016 [28/06/2017]. Available from: Https://en.hdbuzz.net/229
19. Pfizer. Open label extension study to investigate long term safety, tolerability and efficacy of Pf-02545920 in subjects with Huntington's disease who completed study A8241021. https://ClinicalTrials.gov/show/NCT02342548; 2015.
20. Teva Branded Pharmaceutical Products R, Inc. D, European Huntington's Disease Network, Huntington Study Group, Teva Pharmaceutical Industries. A phase 2, to evaluating the safety and efficacy of pridopidine versus placebo for symptomatic treatment in patients with Huntington's disease. https://ClinicalTrials.gov/show/NCT02006472; 2014.
21. Seeman P, Tokita K, Matsumoto M, Matsuo A, Sasamata M, Miyata K. The dopaminergic stabilizer ASP2314/ACR16 selectively interacts with D2(High) receptors. Synapse. 2009;63(10):930-4.
22. Teva Pharmaceutical Industries Ltd. Teva announces results from exploratory 52-week phase 2 PRIDE-HD study of pridopidine in Huntington disease 2016 [Available from: Http://www.tevapharm.com/news/teva announces results rom exploratory 52 week phase 2 pride hd study of prid opidine in huntington disease 09 16.aspx
23. Carroll J, Wild EJ. Sorry folks, the PRIDE-HD trial didNOT showthat Pridopidine slows the progression of Huntington's disease 2016 [Available from: Https://en.hdbuzz.net/227
24. EHDN Executive Committee. Statement of the EHDN Executive Committee about the PRIDE-HD trial 2016 [Available from: Http://www.newshd.net/articles/9641/state ment-of-the-ehdn-executive-committee-about-the-pride-hd-trial.